After the discovery of BRAF-activating mutations in around 50% of cutaneous malignant melanoma (CMM) patients1,2, the development of therapies for disseminated BRAF-mutated CMM has shown promising clinical results. This evidence concerns the gene BRAF and familial congenital mirror movements.